Suchergebnisse - "Mehta, Chetan H"

PubPharm (8)

1

Identification of structural scaffold from interbioscreen (IBS) database to inhibit 3CLpro, PLpro, and RdRp of SARS-CoV-2 using molecular docking and dynamic simulation studies

enthalten in: Journal of biomolecular structure & dynamics | 2023

von Patil, V. | Dhote, A. | Patil, R. | +10

2

Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex

enthalten in: Chemicke zvesti | 2022

von Kumar, B. | Manandhar, S. | Mehta, C. | +2

3

Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex

enthalten in: Chemical papers | 2021

von kumar, B. | Manandhar, S. | Mehta, C. | +2

4

Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex

enthalten in: Chemické zvesti | 2021

von kumar, B. | Manandhar, S. | Mehta, C. | +2

5

Structure-based docking, pharmacokinetic evaluation, and molecular dynamics-guided evaluation of traditional formulation against SARS-CoV-2 spike protein receptor bind domain and ACE2 receptor complex

enthalten in: Chemical papers | 2021

von kumar, B. | Manandhar, S. | Mehta, C. | +2

6

SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2 : An in silico drug repurposing study

enthalten in: European journal of pharmacology | 2021

von Baby, K. | Maity, S. | Mehta, C. | +3

7

Targeting SARS-CoV-2 Main Protease : A Computational Drug Repurposing Study

enthalten in: Archives of medical research | 2021

von Baby, K. | Maity, S. | Mehta, C. | +3

8

Targeting SARS-CoV-2 RNA-dependent RNA polymerase : An in silico drug repurposing for COVID-19

enthalten in: F1000Research | 2020

von Baby, K. | Maity, S. | Mehta, C. | +3

1
[1]